Logo

Oculis Holding AG

OCS

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the tre… read more

Healthcare

Biotechnology

2 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$17.47

Price

-0.66%

-$0.11

Market Cap

$914.044m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financials Overview

Key metrics over the past few years

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

-$107.433m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$2.35

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$143.096m

$181.621m

Assets

$38.525m

Liabilities

$1.030m

Debt
Debt to Assets

0.6%

-

Debt to EBITDA
Free Cash Flow

-$58.431m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Earnings and other important metrics. Amounts in CHF.
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases